ATRX and neuroblastoma: Despite extensive genome and transcriptome sequencing analyses, oncogenic mutations in neuroblastoma are comparatively rare compared to other cancers [1], [2], although genome-wide analyses have implicated complex deregulatory events such as enhancer hijacking, leading to Telomerase reverse transcriptase (TERT) over-expression and ATRX inactivation in non-MNA high-risk neuroblastoma [3], [4].